UB Paderborn / Katalog / Suche / in CDI

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

The lancet oncology, 2019-01, Vol.20 (1), p.31-42

2019

Volltextzugriff (PDF)

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Blood advances, 2020-10, Vol.4 (19), p.4898-4911

2020

Volltextzugriff (PDF)

Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2007-06, Vol.25 (17), p.2369-2376

2007

Volltextzugriff (PDF)

Characterization and Cell Cycle Regulation of the Major Kaposi’s Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Latent Genes and Their Promoter

Journal of Virology, 1999-02, Vol.73 (2), p.1438-1446

1999

Volltextzugriff (PDF)

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

The New England journal of medicine, 2022-02, Vol.386 (7), p.640-654

2022

Volltextzugriff (PDF)

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

The New England journal of medicine, 2023-07, Vol.389 (2), p.148-157

2023

Volltextzugriff (PDF)

Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Blood, 2017-12, Vol.130, p.2826-2826

2017

Volltextzugriff (PDF)

ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS7075-TPS7075

2016

Volltextzugriff (PDF)

Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3024-3024

2017

Volltextzugriff (PDF)

Zuma-6: Phase 1-2 multicenter study evaluating safety and efficacy of axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab in patients with refractory diffuse large b-cell lymphoma (DLBCL)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS7572-TPS7572

2017

Volltextzugriff (PDF)

Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Blood, 2017-12, Vol.130 (Suppl_1), p.888-888

2017

Volltextzugriff (PDF)

Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

Blood, 2017-12, Vol.130 (Suppl_1), p.1547-1547

2017

Volltextzugriff (PDF)

Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7559-7559

2016

Volltextzugriff (PDF)

Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with axicabtagene ciloleucel (axi-cel)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3023-3023

2017

Volltextzugriff (PDF)

Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.7512-7512

2017

Volltextzugriff (PDF)

Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3025-3025

2017

Volltextzugriff (PDF)

Biomarker analysis of patients treated with anti-CD19 chimeric antigen receptor (CAR) T cells

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3028-3028

2015

Volltextzugriff (PDF)

Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7516-7516

2016

Volltextzugriff (PDF)

Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.3581-3581

2012

Volltextzugriff (PDF)

Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab)

Journal of clinical oncology, 2012-02, Vol.30 (4_suppl), p.383-383

2012

Volltextzugriff (PDF)

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3511-3511

2013

Volltextzugriff (PDF)

Rapid conversion to high xanthine oxidase activity in viable Kupffer cells during hypoxia

The Journal of clinical investigation, 1994-12, Vol.94 (6), p.2224-2230

1994

Volltextzugriff (PDF)

Death Receptor Agonists as a Targeted Therapy for Cancer

Clinical cancer research, 2010-03, Vol.16 (6), p.1701-1708

2010

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors

Characterization and Cell Cycle Regulation of the Major Kaposi’s Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Latent Genes and Their Promoter

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL)

Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL)

Zuma-6: Phase 1-2 multicenter study evaluating safety and efficacy of axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab in patients with refractory diffuse large b-cell lymphoma (DLBCL)

A Comparison of One Year Outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with Refractory, Aggressive Non-Hodgkinlymphoma (NHL)

Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL)

Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with axicabtagene ciloleucel (axi-cel)

Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL)

Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19)

Biomarker analysis of patients treated with anti-CD19 chimeric antigen receptor (CAR) T cells

Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study

Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab)

Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab)

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC)

Rapid conversion to high xanthine oxidase activity in viable Kupffer cells during hypoxia

Death Receptor Agonists as a Targeted Therapy for Cancer

Suchergebnisse filtern